ABSTRACT
Group B Streptococcus (GBS) is a major etiologic agent of neonatal bacterial infections and is the most common cause of sepsis and pneumonia in newborns. Surface and secreted molecules of GBS are often essential virulence factors which are involved in the adherence of the bacteria to host cells or are required to suppress the defense mechanisms of hosts. We analyzed the peptidase profiles of GBS by detection of proteolytic activities on SDS-PAGE containing copolymerized gelatin as substrate. Based on the inhibition by o-phenathroline and EGTA, three distinct peptidases of 220, 200 and 180 kDa were identified in the culture medium, besides one major cell-associated proteolytic activity, a 200-kDa metallopeptidase, suggesting that all were zinc-metallopeptidases. GBS culture supernatants, rich in metallotype peptidases, also cleaved fibronectin, laminin, type IV collagen, fibrinogen and albumin. Cleavage of the host extracellular matrix by GBS may be a relevant factor in the process of bacterial dissemination and/or invasion. Notably, metallopeptidase inhibitors strongly blocked GBS growth as well as its interaction with human cell lineages. Understanding the contribution of peptidases to the pathogenesis of GBS disease may broaden our perception of how this significant pathogen causes severe infections in newborn infants.
Subject(s)
Cell Lineage/drug effects , Metalloproteases/metabolism , Protease Inhibitors/pharmacology , Streptococcus agalactiae/cytology , Streptococcus agalactiae/enzymology , Cell Line , Cell Proliferation/drug effects , Humans , Protein Processing, Post-Translational/drug effects , Streptococcus agalactiae/drug effectsABSTRACT
Light and electron microscopy were used to analyse the process of interaction of Streptococcus agalactiae (serotypes Ia, III, and V) with resident and activated mouse peritoneal macrophages. Transmission electron microscopy showed that adherence of the S. agalactiae serotype Ia, but not III and V serotypes, to the surface of activated macrophages triggers the respiratory oxidative burst as revealed by the presence of reduced nicotinamide adenine dinucleotide (phosphate) [NAD(P)H]-oxidase in the phagocytic vacuoles. Fusion of macrophage lysosomes with bacteria-containing phagocytic vacuoles was observed in macrophages treated with Lucifer yellow as well as by localization of acid phosphatase for all serotypes.
Subject(s)
Macrophages, Peritoneal/cytology , Macrophages, Peritoneal/microbiology , Streptococcus agalactiae/cytology , Streptococcus agalactiae/physiology , Acid Phosphatase/metabolism , Animals , Cells, Cultured , Histocytochemistry , Isoquinolines , Lysosomes/microbiology , Lysosomes/physiology , Lysosomes/ultrastructure , Macrophage Activation , Macrophages, Peritoneal/ultrastructure , Mice , Microscopy, Confocal , Microscopy, Electron , NADPH Oxidases/metabolism , Phagosomes/microbiology , Phagosomes/physiology , Phagosomes/ultrastructure , Respiratory Burst , Streptococcus agalactiae/classification , Streptococcus agalactiae/ultrastructureABSTRACT
OBJECTIVES: To evaluate the effects of different surfactants on pulmonary infection with group B streptococci in premature rabbits and to examine the effects of different surfactants on pulmonary alveolar macrophage function of newborn rabbits. MODEL: Preterm and term rabbit pups. METHODS: Rabbit pups were infected with GBS aerosols followed by intratracheal administration of either calf lung surfactant extract, minced porcine lung surfactant (Curosurf), synthetic surfactant (Exosurf Neonatal), minced bovine lung surfactant (Survanta), human amniotic fluid-derived surfactant, rabbit surfactant, saline vehicle, or no treatment. Intrapulmonary clearance of GBS was determined by comparing bacterial counts in left lungs cultured immediately after aerosol infection with similarly infected lungs analyzed 4 hours after surfactant therapy. Phagocytosis of streptococci was ascertained by microscopic examination of the right lungs fixed in situ at 4 hours. For comparison, an in vitro method was used to measure growth of GBS in the different surfactants. RESULTS: Preterm animals had a sixfold increase in pulmonary bacterial growth compared with a slight decrease in intrapulmonary GBS in term animals when all were delivered by cesarean section (p < 0.05). In premature rabbits, GBS proliferation was lowest in animals treated with Exosurf Neonatal and highest in animals receiving Curosurf and human amniotic fluid-derived surfactant (p < 0.05). None of the surfactants promoted accelerated growth of GBS in comparison with control animals. Similar growth of GBS was seen in in vitro cultures. Intrapulmonary phagocytosis of GBS in premature pups was not altered by any of the surfactants. In term rabbit pups, the following measures of macrophage population kinetics remained normal at 1 and 24 hours after surfactant administration: viability, cell numbers based on lung lavage, and in vivo incorporation of thymidine. CONCLUSIONS: Surfactants used in clinical practice do not accelerate the in vivo growth of group B streptococci in the lungs of preterm rabbits. Some surfactants inhibit streptococcal proliferation. The effects of different surfactants are not explained by changes in macrophage function.